Optiver Holding
ALLO icon

Optiver Holding’s Allogene Therapeutics ALLO Stock Holding History

Optiver Holding’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98K Sell
954
-480
-33% -$1.05K ﹤0.01% 2314
2026
Q1 		$3.5K Buy
1,434
+392
+38% +$786 ﹤0.01% 1582
2025
Q4 		$1.43K Hold
1,042
– – ﹤0.01% 2133
2025
Q3 		$1.29K Sell
1,042
-66
-6% -$79 ﹤0.01% 2471
2025
Q2 		$1.25K Hold
1,108
– – ﹤0.01% 1378
2025
Q1 		$1.62K Buy
1,108
+971
+709% +$1.83K ﹤0.01% 1250
2024
Q4 		$292 Buy
+137
New +$338 ﹤0.01% 1017

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Optiver Holding's ALLO Position: Q2 2026 in Review

Optiver Holding reduced its Allogene Therapeutics (ALLO) stake by 33% in Q2 2026, selling an estimated $1.05K and leaving 954 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #2314.

Optiver Holding first reported a position in ALLO in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.5K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Optiver Holding held 954 shares of Allogene Therapeutics worth $1.98K as of Q2 2026.
  • Optiver Holding sold 480 Allogene Therapeutics shares in Q2 2026, an estimated $1.05K.
  • Allogene Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2314 holding.
  • Optiver Holding first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Optiver Holding's Allogene Therapeutics position peaked at $3.5K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.